http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2706185-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dcb0dde0aefda78540321dfccbddb40a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate | 2010-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81165c5611c1e95b9ff36419ef9052dc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a572178918dc1c1cd9c58c16ca96280a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_551179b7993f1b5c322d0b3f05d5426c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d898b672c1e1d886a7ea2a33b8c5af6 |
| publicationDate | 2019-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2706185-T3 |
| titleOfInvention | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their uses in cancer therapy |
| abstract | A compound of formula I, IA or IB: ** Formula ** or an enantiomer, a mixture of enantiomers, or a mixture of two or more of its diastereoisomers; or its acceptable pharmaceutical salt, solvate or hydrate; where: each R1 is independently hydrogen, C1-6 alkyl, -S-C1-6 alkyl, -S (O) -C1-6 alkyl, or -SO2-C1-6 alkyl each R2 and R3 is, independently, (a ) hydrogen, cyano, halo or nitro; (b) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl or heterocyclyl; or (c) -C (O) R1a, -C (O) OR1b, -C (O) NR1bR1c, -C (NRa) NR1bR1c, -OR1a, -OC (O) R1a, -OC (O) OR1a, - OC (O) NR1bR1c, - OC (= NR1a) NR1bR1c, -OS (O) R1a, -OS (O) 2R1a, -OS (O) NR1bR1c, -OS (O) 2NR1bR1c, -NR1bR1c, -NR1aC (O) R1d, - NR1aC (O) OR1d, -NR1aC (O) NR1bR1c, -NR1aC (= NR1d) NR1bR1c, -NR1aS (O) R1d, -NR1aS (O) 2R1d, -NR1aS (O) NR1bR1c, - NR1a 2NR1bR1c, -SR1a, -S (O) R1a, -S (O) 2R1a, -S (O) NR1bR1c, oS (O) 2NR1bR1c; each R4 and R5 is independently hydrogen or C1-6 alkyl or R4 and R5 linked to form a bond, C1-6 alkylene, C1-6 heteroalkylene, C2-6 alkenylene, or C2-6 heteroalkenylene; each R6 is independent C7-15 aralkyl, C6-14 aryl, heteroaryl, or heteroaryl-C1-6 alkyl; each U is independently -NR1a-, -C (O) -, -C (O) O-, -C (O) NR1a-, -O-, -OC (O) O-, -OC (O) NR1a- , -NR1aC (O) NR1d-, - NR1aS (O) -, -NR1aS (O) 2-, -NR1aS (O) NR1d-, -NR1aS (O) 2NR1d-, -S-, -S (O) - , or -S (O) 2-; each X, Y and Z is N; each A, B, D, and E is independently a bond, C, O, N, S, NR9, CR9 or CR9R10, where each R9 and R10 is independently hydrogen, halo, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl; where the bonds between A, B, D and E can be saturated or unsaturated; with the proviso that not more than one of A, B, D and E are a bond; each R1a, R1b, R1c and R1d is, independently, (i) hydrogen; or (ii) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl or heterocyclyl; wherein each alkyl, alkylene, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl at R1, R2, R3, R4, R5, R6, R9, R10, R1a, R1b, R1c or R1d is optionally substituted by one or more groups, each independently selected from (a) cyano, halo and nitro; (b) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted by one or more Q substituents; and (c) -C (O) Ra, -C (O) ORa, -C (O) NRbRc, -C (NRa) NRbRc, -ORa, -OC (O) Ra, -OC (O) ORa, - OC (O) NRbRc, -OC (= NRa) NRbRc, -OS (O) Ra, -OS (O) 2Ra, -OS (O) NRbRc, -OS (O) 2NRbRc, -NRbRc, -NRaC (O) Rd, -NRaC (O) Od, -NRaC (O) NRbRc, -NRaC (= NRd) NRbRc, -NRaS (O) Rd, - NRaS (O) NRbRc, -SRa, -S (O) Ra, and - S (O) NRbRc, where each Ra, Rb, Rc and Rd is, independently, (i) hydrogen; (ii) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl, each optionally substituted by one or more Q substituents; or (iii) Rb and Rc, together with the N atom to which they are attached, form heterocyclyl, optionally substituted by one or more Q substituents; where each Q is independently selected from the group consisting of (a) cyano, halo and nitro; (b) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, and heterocyclyl; and (c) -C (O) Re, - C (O) ORe, -C (O) NRfRg, -C (NRe) NRfRg, -ORe, -OC (O) Re, -OC (O) ORe, - OC (O) NRfRg, -OC (= NRe) NRfRg, -OS (O) Re, - OS (O) 2Re, -OS (O) NRfRg, -OS (O) 2NRfRg, -NRfRg, -NReC (O) Rh, -NReC (O) ORh, -NReC (O) NRfRg, -NReC (= NRh) NRfRg, - NReS (O) Rh, -NReS (O) NRfRg, -SRe, -S (O) Re, and - S (O) NRfRg, where each Re, Rf, Rg and Rh is, independently, (i) hydrogen; (ii) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl or heterocyclyl; or (iii) Rf and Rg, together with the N atom to which they are attached, form heterocyclyl. |
| priorityDate | 2009-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1193.